Ravin Consultants Pivots Leadership to Tackle 340B Program Complexity

BRADENTON, FL – April 09, 2026 – In a strategic move designed to navigate an increasingly contentious environment, Ravin Consultants, a nationally recognized 340B consulting firm, has announced a significant evolution of its leadership team. Founder Jennifer Lockwood has transitioned to the newly created role of Executive Chair, while Dr. Robert Ferraro, a long-tenured executive within the company, has been promoted to Chief Executive Officer.

The shuffle, which also includes the promotions of Dr. Jaclyn Hahn to Chief Operating Officer and Lauren Navas to Chief Growth Officer, is being framed by the company as an intentional strategy to fortify its operations and advocacy efforts. This change comes as the federal 340B Drug Pricing Program, a critical financial lifeline for healthcare organizations serving vulnerable populations, faces unprecedented legal, regulatory, and political challenges.

“This transition is intentional,” said Lockwood in a statement. “Ravin Consultants was built to endure. As the 340B environment becomes more complex and scrutinized, I want to focus my energy where I can create lasting impact for our clients and for the future of this program.”

Navigating a Turbulent Landscape

The leadership restructuring at Ravin Consultants is not occurring in a vacuum. It is a direct response to the mounting pressures on the 340B program. For years, covered entities—the hospitals and clinics that qualify for the program—have grappled with an escalating series of hurdles. A primary point of conflict has been the wave of restrictions imposed by major drug manufacturers, which have limited or refused to offer discounted pricing for drugs dispensed through community-based contract pharmacies. This has sparked a flurry of litigation across the country, resulting in conflicting court decisions and a pervasive sense of uncertainty for healthcare providers.

Simultaneously, the Health Resources and Services Administration (HRSA), the federal agency overseeing the program, has ramped up its audit and enforcement activities. Audit findings from recent fiscal years reveal a sharp focus on compliance issues related to diversion and duplicate discounts, putting immense pressure on organizations to maintain flawless documentation and program integrity.

Adding another layer of complexity is the proposed introduction of a voluntary 340B Rebate Model Pilot Program. This model would shift from the traditional upfront discount to a post-purchase rebate system, a change that could severely strain the cash flow of safety-net hospitals that rely on the immediate savings to fund patient care services. These developments, combined with persistent calls from some corners of Washington for legislative reform and increased transparency, have created a high-stakes environment where specialized expertise and high-level advocacy are more critical than ever.

A New Era of Data-Driven Leadership

Stepping into this challenging landscape as CEO is Dr. Robert Ferraro, a leader whose background appears tailor-made for the current moment. With nearly two decades of pharmacy experience and over a decade in executive roles, Dr. Ferraro has been a senior leader at Ravin for more than six years. He has been instrumental in building the company's operational infrastructure and championing its disciplined, data-driven approach.

His credentials underscore a deep commitment to both clinical precision and operational efficiency. Dr. Ferraro holds a Doctor of Pharmacy, an MBA, a Six Sigma Green Belt in Healthcare Operations, and certifications as a 340B Apexus Expert (ACE) and in AI Prompting. This unique blend of clinical knowledge, business strategy, and technological fluency positions him to lead the company’s efforts in delivering measurable, optimized results for clients.

“I am grateful for the opportunity to continue building on what Jennifer created,” stated Dr. Ferraro. “The expectations she set around expertise and integrity will remain central to how we operate. My focus is to ensure we continue delivering meaningful, measurable results for our clients as the landscape evolves.”

Supporting Dr. Ferraro is a newly solidified executive team. As Chief Operating Officer, Dr. Jaclyn Hahn will be tasked with ensuring the “flawless operational delivery” of all company services. Lauren Navas, as the new Chief Growth Officer, will helm strategic initiatives in marketing and business development, aiming to expand the firm’s reach and impact.

The Founder's Next Chapter: Advocacy and Vision

Jennifer Lockwood’s transition from founder and CEO to Executive Chair marks a pivotal moment for both her and the company she built. Under her leadership, Ravin Consultants grew from a concept into one of the country's most respected independent 340B consulting firms. Its rapid expansion earned it a spot on the Inc. 5000 list of fastest-growing private companies for two consecutive years, alongside recognition on the Top 100 Women-Led Businesses in Florida and Inc.'s Top Female Founders 500 list.

Her new role leverages this legacy, redirecting her focus from internal, day-to-day management to the external, macro-level challenges facing the 340B program. As Executive Chair, Lockwood will concentrate on long-term strategy, forging key industry partnerships, and, most critically, dedicating her efforts to 340B advocacy. This move effectively creates a two-pronged leadership approach for the firm: Dr. Ferraro’s team will focus on executing with precision for clients, while Lockwood engages in the broader fight to protect and strengthen the program’s ecosystem.

This shift allows a seasoned founder, who built a company on the premise that the 340B program deserved specialized expertise, to become a dedicated voice for the program itself. Her work will aim to influence policy and build coalitions that support the mission of the hundreds of healthcare organizations that depend on 340B savings to care for their communities' most vulnerable patients.

By restructuring its leadership, Ravin Consultants is adapting to the new reality of the 340B world. The company is betting that success in the coming years will require both impeccable internal operations and influential external advocacy. With a data-driven operator at the helm and a passionate founder leading the strategic charge, the firm is positioning itself not just to weather the ongoing turbulence but to help its clients and the broader 340B community navigate it with confidence.